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Introduction: Glaucoma patients frequently exhibit ocular surface side effects during treatment 
with prostaglandin eye drops. The present work investigated whether glaucoma patients suffer-
ing from signs and symptoms of ocular surface disease while using preserved latanoprost eye 
drops benefited from switching to preservative-free tafluprost eye drops.
Patients and methods: The analysis was based on 339 glaucoma patients enrolled in two Phase 
IIIb trials. The patients were required to have two symptoms, or one sign and one symptom of 
ocular surface disease at baseline, and at least 6 months preceding treatment with latanoprost eye 
drops preserved with benzalkonium chloride. All eligible patients were switched from latanoprost 
to preservative-free tafluprost for a total of 12 weeks. Ocular symptoms and ocular signs were 
evaluated at baseline and at 2 weeks, 6 weeks, and 12 weeks after commencing treatment with 
tafluprost. Intraocular pressure (IOP), drop discomfort, and treatment preference were evaluated 
to investigate the clinical efficacy and patient-related outcomes.
Results: After 12 weeks of treatment with preservative-free tafluprost, the incidences of 
irritation/burning/stinging, foreign body sensation, tearing, itching, and dry eye sensation had 
diminished to one-third of those reported for preserved latanoprost at baseline. The incidences 
of blepharitis and corneal/conjunctival fluorescein staining had in turn decreased to one-half 
of those reported for preserved latanoprost. Severity of conjunctival hyperemia was halved 
during treatment with preservative-free tafluprost, and there was significant improvement in 
tear break-up time and tear production. A further reduction in IOP (~1 mmHg) was seen with 
preservative-free tafluprost compared with preserved latanoprost. Drop discomfort was allevi-
ated during preservative-free tafluprost treatment, and an outstanding majority of patients (72%) 
preferred preservative-free tafluprost over preserved latanoprost.
Conclusion: This meta-analysis confirmed that IOP remained at the same level after replacing 
benzalkonium chloride-preserved latanoprost eye drops with preservative-free tafluprost eye 
drops. Preservative-free tafluprost significantly decreased the symptoms and signs of ocular 
surface disease and outrated latanoprost in drop comfort and treatment preference.
Keywords: Taflotan®, preserved latanoprost, Xalatan®, ocular surface disease, ocular symptoms 
and signs, IOP, patient-related outcome
Introduction
Several studies have recently illustrated that a large number of glaucoma patients using 
topical drugs suffer from concomitant ocular surface disease.1–3 According to those stud-
ies, as much as half of these patients appear to encounter dry eye symptoms. It has further 
been demonstrated that the preservative – mostly benzalkonium chloride (BAC) – is 
the causative agent leading to the symptoms of dry eye. Thus, the adverse preservative 
effects constitute a significant clinical problem in the treatment of glaucoma.
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BAC is most commonly used with concentrations ranging 
from 0.004% to 0.02% in the antiglaucoma medications; 
within this range, it is toxic in a dose-dependent manner. 
BAC has been shown to have direct toxicity to various 
tissues of the ocular surface and causes adverse effects, 
such as conjunctival hyperemia, punctate keratopathy, and 
epithelial erosions. In addition, accumulation of signs and 
symptoms, such as irritation/burning/stinging, itching, for-
eign body sensation, tearing, and dry eye sensation, has been 
reported.4,5 Glaucoma drugs that contain a preservative have 
been incriminated in reducing the number of goblet cells, 
increasing the subepithelial collagen deposition, expanding 
the substantia propria with an infiltrate of chronic inflamma-
tory cells, and even exhibiting a proapoptotic effect in the 
conjunctiva.6–11 The use of antiglaucoma drugs in general and 
BAC-containing drugs particularly has been directly linked 
to the failure of glaucoma surgery.9,12 Tafluprost 0.0015% 
ophthalmic solution (Taflotan®, Saflutan®; Santen, Osaka, 
Japan) was the first preservative-free prostaglandin medica-
tion developed for the treatment of glaucoma; it has a proven 
preclinical and clinical intraocular pressure (IOP)-lowering 
efficacy.13–19 Tafluprost is a prodrug of synthetic analog of 
prostaglandin F
2α and acts on prostaglandin F prostanoid 
receptors with high affinity and selectivity. The pharma-
cological mechanism of action of tafluprost is analogous 
to that of latanoprost 0.005% (Xalatan®; Pfizer, Inc., New 
York, NY, USA) and travoprost 0.004% (Travatan®; Alcon, 
Inc., Fort Worth, TX, USA) ophthalmic solutions, whereas 
bimatoprost 0.03% (Lumigan®; Allergan, Inc., Irvine, CA, 
USA) can be regarded as both a prostaglandin prodrug and 
a prostamide.
The aim of this paper is to present the meta-analysis 
results of two independent clinical Phase IIIb studies, among 
which the first study was published as a full paper and the 
second published only in the local language.20,21 Both studies 
in question had an identical design and recruited glaucoma 
patients who had developed signs and symptoms of ocular 
surface disease during treatment with preserved latano-
prost eye drops (containing a high 0.02% concentration of 
BAC). The preserved latanoprost eye drops were switched 
to preservative-free tafluprost eye drops after the baseline 
visit for a period of 12 weeks. Especially, ocular signs and 
symptoms, IOP, drop discomfort, and patient preference were 
evaluated and pooled across the studies for the purpose of 
this meta-analysis.
Patients and methods
The meta-analysis was based on two independent, open-
label, multicenter, Phase IIIb clinical studies: one performed 
in Finland, Sweden, and Germany during 2008 and the 
other in Russia during 2010.20,21 A total of 158 patients 
from 12 centers were enrolled in the first study, whereas 
185 patients from seven centers were enrolled in the second 
study. Both studies adopted an essentially identical study 
protocol with the exception that impression cytology of the 
conjunctiva was performed only in the first study.20 Open-
label designs were used, since the preservative-free tafluprost 
eye drops were commercially available only in unit dose 
dispensers and not in conventional multidose bottles as with 
preserved latanoprost.
The two studies were completed in compliance with 
the Good Clinical Practice guideline of the International 
Conference on Harmonization and the Declaration of 
Helsinki. The study protocols were approved by the local 
Independent Ethics Committees and the National Competent 
Authority. Written informed consent was provided by each 
patient before inclusion in the study.
Patients of either sex aged 18 years or older were screened 
for the two studies. Eligible patients were required to have 
a diagnosis of ocular hypertension (OH) or open-angle 
glaucoma (OAG) in either eye or both eyes and at least 
6 months preceding instillation of preserved latanoprost 
eye drops. OAG comprised primary OAG and pseudoex-
foliative glaucoma (PEX). The presence of at least 1) two 
symptoms or 2) one sign and one symptom of ocular surface 
disease was imperative for all patients at the screening visit 
(Table 1). Additional inclusion criteria were best-corrected 
visual acuity score of +0.6 logarithm of the minimum angle 
Table 1 Eligibility (abnormality) criteria for the symptoms and 
signs of ocular surface disease in the individual studies
Ocular symptom Grading Eligibility criteria
Irritation/burning/stinging 0–4a at least grade 2
Foreign body sensation 0–4a at least grade 2
Tearing 0–4a at least grade 2
itching 0–4a at least grade 2
Dry eye sensation 0–4a at least grade 2
Ocular sign Unit/grading Eligibility criteria
Fluorescein tear break-up time 
(tBUT)
secondsb ,10 seconds
Corneal fluorescein staining 0–Vc at least grade i
Conjunctival fluorescein staining 0–Xd at least grade ii
Blepharitis 0–3e at least grade 1
Conjunctival hyperemia 0–4f at least grade 1
Tear production mmg #10 mm
Notes: For ocular symptoms, the treated eyes were considered together, whereas 
the signs were evaluated by eye (and the analyses were based on the eye with 
the worse grading). a0= none, 1= trace, 2= mild, 3= moderate, and 4= severe. bslit 
lamp microscope. cOxford grading scale (0–V). dCombined nasal (0–V) and temporal 
(0–V) score by Oxford grading scale. e0= none, 1= mild, 2= moderate, and 3= severe. 
fRedness scale with reference photographs (half grades allowed); 0= none, 1= mild, 
2= moderate, 3= severe, and 4= very severe. gschirmer’s test.
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of resolution (logMAR) or better in both eyes (based on 
early treatment diabetic retinopathy study eye charts) and 
willingness to follow instructions and provision of a written 
informed consent.
Ocular exclusion criteria were anterior chamber angle ,2 
(by gonioscopy and Shaffer’s classification), corneal abnor-
mality or other condition (such as prior refractive eye surgery) 
preventing reliable applanation tonometry, IOP .22 mmHg 
(at 3 pm with preserved latanoprost), use of preserved 
artificial tears during the past 2 weeks, diagnosis of angle-
closure glaucoma or secondary glaucoma other than PEX, 
contraindication or hypersensitivity to tafluprost, glaucoma 
filtration surgery or any other ocular surgery (including laser 
procedures) within 6 months prior to screening, and use of 
contact lenses. Systemic exclusion criteria were pregnancy 
or lactation, unwillingness to avoid pregnancy, and current 
alcohol or drug abuse. In addition, any ocular or systemic 
condition (such as aphakia or diabetes) that could put the 
patient at risk, confound the results, or interfere with the 
patient’s participation in the study was a cause of exclusion. 
Participation in another investigational drug (or device) study 
during the past 30 days was also prohibited.
Standard ophthalmic procedures were used to investigate 
the study patients. Ocular symptoms and signs were queried/
assessed using the scales and tests mentioned in Table 1. IOP 
was measured (in mmHg) by applanation tonometry. Drop dis-
comfort was evaluated using a four-grade scale: no, mild, mod-
erate, or severe discomfort. Quality-of-life (QoL) assessments 
utilized a validated questionnaire for comparing the tolerabil-
ity of ophthalmic medications (COMTol).22 The questionnaire 
was managed by an interviewer at each study clinic. Patients’ 
preference for the treatment options (preserved latanoprost or 
preservative-free tafluprost) was evaluated within this ques-
tionnaire using a three-grade scale: latanoprost, tafluprost, or 
neither. Adverse events were queried, visual acuity (logMAR 
score) and visual field were tested, and biomicroscopic and 
ophthalmoscopic findings were evaluated in order to further 
assess the safety of the patients.
Both studies accommodated a total of five visits to 
the clinic. The treatment period included a consolidated 
screening/baseline visit and subsequent visits 2 weeks, 
6 weeks, and 12 weeks after commencing once-daily treat-
ment with preservative-free tafluprost in the evening of the 
baseline visit. A post-study visit was scheduled 1–3 weeks 
after the cessation of tafluprost treatment at 12 weeks. All 
the aforementioned examinations were done at the base-
line visit. The examinations were renewed at the 2-week, 
6-week, and 12-week visits, apart from visual field test and 
ophthalmoscopy (redone at 12 weeks only). At the post-
study visit, in turn, all examinations were done besides the 
assessment of ocular symptoms and signs, drop discomfort, 
and treatment preference (QoL). All study procedures were 
performed at approximately the same time of the day dur-
ing the course of the study; for example, IOP was measured 
invariably at 3 pm ±1 hour.
Sample size calculations were done for both studies. An 
occurrence of 40%–50% was anticipated for a single ocular 
symptom or sign (such as foreign body sensation) at baseline. 
In other words, 40%–50% of the patients were expected to 
experience at least mild foreign body sensation at the base-
line visit. A decrease of 10% in the incidence of a single 
symptom or sign was then regarded as a reasonable basis for 
sample size calculations. Making use of this assumption and 
McNemar’s test (with a two-sided type I error of 5% and a 
power of 80%), at least 150 eligible patients needed to be 
enrolled in each study. The actual sample sizes satisfied this 
criterion (Table 2) and added up to a total of 343 patients 
included in this meta-analysis.
Individual data were available for both studies. The 
results were summarized at baseline (preserved latano-
prost) and at 6-week and 12-week visits (preservative-free 
tafluprost). A statistical model including fixed effects for 
Table 2 Demographic characteristics of the patients at baseline in the individual studies and the entire meta-analysis cohort
Variable Study 1a Study 2b Meta-analysis
Number of patients 158 185 343
sex
Male n (%) 54 (34.2%) 75 (40.5%) 129 (37.6%)
Female n (%) 104 (65.8%) 110 (59.5%) 214 (62.4%)
Age in years, median (max–min) 69 (37–88) 63 (23–84) 67 (23–88)
Primary open-angle glaucoma n (%) 109 (69.0%) 183 (98.9%) 292 (85.1%)
Pseudoexfoliative glaucoma n (%) 16 (10.1%) 1 (0.5%) 17 (5.0%)
Ocular hypertension n (%) 33 (20.9%) 1 (0.5%) 34 (9.9%)
Notes: In three patients, one eye was diagnosed with primary open-angle glaucoma and the other eye with ocular hypertension; these patients were categorized as primary 
open-angle glaucoma. In an additional three patients, one eye was diagnosed with primary open-angle glaucoma and the other eye with pseudoexfoliative glaucoma; these 
patients were included as pseudoexfoliative glaucoma. aStudy performed in Finland, Sweden, and Germany. bStudy performed in Russia.
Abbreviations: max, maximum; min, minimum.
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study (between-patient effect), treatment (within-patient 
effect), and their interaction was fitted for the study variables. 
A parametric analysis method was used for IOP, conjuncti-
val redness, tear break-up time (tBUT), and tear production 
(Schirmer’s test), and a corresponding nonparametric analy-
sis method was used for the remaining study variables that 
were tested statistically.23 As no real evidence of heterogene-
ity was detected between the two studies, the final analyses 
did not incorporate the interaction effect.
Results
All results are provided as means and standard deviations for 
continuous variables and frequencies and percentages (%) 
for ordinal variables, unless otherwise indicated. A summary 
of the demographic characteristics of the study patients is 
displayed in Table 2. Both studies succeeded in enrolling 
representative samples of OH/OAG patients with comparable 
distributions of age and sex. The overall mean age of the 
patients was 67 years (range 23–88 years). Approximately 
two-thirds of the patients were females (62.4%). A majority 
of the patients were diagnosed with primary OAG (85.1%) 
and only one-tenth with OH (9.9%) and one-20th with PEX 
(5.0%). Only 27 (7.9%) patients discontinued the studies 
prematurely. The most common causes of discontinuation 
were protocol deviation (nine patients), adverse event (nine 
patients), and patient request (six patients). Four of the 
discontinued patients did not have any postbaseline data. 
Consequently, the overall results are summarized for a cohort 
of 339 patients in the sequel.
Ocular symptoms
The frequency distributions of ocular symptoms are sum-
marized in Table 3 by study visit. All five symptoms were 
prevalent at baseline with preserved latanoprost. Mild- 
to-severe irritation/burning/stinging, foreign body sensation, 
tearing, itching, and dry eye sensation were reported by 59.6%, 
Table 3 Number (%) of patients experiencing ocular symptoms (irritation/burning/stinging, foreign body sensation, tearing, itching, and 
dry eye sensation) or ocular sign (blepharitis) at baseline during treatment with preserved latanoprost and after 6 weeks and 12 weeks 
of treatment with preservative-free tafluprost
Symptoms/signs of 
ocular surface disease
Severity 
grade
Baseline preserved 
latanoprost (N=339)
6 weeks* preservative-
free tafluprost (N=318)
12 weeks* preservative-
free tafluprost (N=316)
Irritation/burning/stinging none 97 (28.6%) 187 (58.8%) 210 (66.5%)
Trace 40 (11.8%) 62 (19.5%) 53 (16.8%)
Mild 113 (33.3%) 36 (11.3%) 29 (9.2%)
Moderate 75 (22.1%) 31 (9.7%) 24 (7.6%)
severe 14 (4.1%) 2 (0.6%) 0 (0.0%)
Foreign body sensation none 166 (49.0%) 233 (73.3%) 252 (79.7%)
Trace 38 (11.2%) 35 (11.0%) 20 (6.3%)
Mild 76 (22.4%) 32 (10.1%) 27 (8.5%)
Moderate 47 (13.9%) 16 (5.0%) 15 (4.7%)
severe 12 (3.5%) 2 (0.6%) 2 (0.6%) 
Tearing none 157 (46.3%) 222 (69.8%) 232 (73.4%)
Trace 44 (13.0%) 44 (13.8%) 36 (11.4%)
Mild 59 (17.4%) 33 (10.4%) 33 (10.4%)
Moderate 56 (16.5%) 17 (5.3%) 12 (3.8%)
severe 23 (6.8%) 2 (0.6%) 3 (0.9%)
itching none 183 (54.0%) 213 (67.0%) 226 (71.5%)
Trace 40 (11.8%) 53 (16.7%) 43 (13.6%)
Mild 67 (19.8%) 35 (11.0%) 30 (9.5%)
Moderate 38 (11.2%) 15 (4.7%) 14 (4.4%)
severe 11 (3.2%) 2 (0.6%) 3 (0.9%)
Dry eye sensation none 111 (32.7%) 177 (55.7%) 202 (63.9%)
Trace 32 (9.4%) 61 (19.2%) 41 (13.0%)
Mild 87 (25.7%) 50 (15.7%) 49 (15.5%)
Moderate 85 (25.1%) 25 (7.9%) 22 (7.0%)
severe 24 (7.1%) 5 (1.6%) 2 (0.6%)
Blepharitis none 135 (39.8%) 195 (61.3%) 208 (65.8%)
Mild 159 (46.9%) 118 (37.1%) 105 (33.2%)
Moderate 44 (13.0%) 5 (1.6%) 3 (0.9%)
severe 1 (0.3%) 0 (0.0%) 0 (0.0%)
Notes: *The changes from baseline at 6 weeks and 12 weeks were statistically significant; P,0.001.
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39.8%, 40.7%, 34.2%, and 57.8% of the patients, respectively 
(Figure 1). A statistically significant shift (P,0.001) toward 
less severe symptoms was already seen 6 weeks after the 
switch to preservative-free tafluprost. The percentages of 
patients with no or only a trace of a symptom increased remark-
ably, and the percentages of patients with mild-to-severe 
symptoms decreased accordingly. A continued improvement 
was seen in all symptoms from 6 weeks to 12 weeks, but 
to a lesser extent. At the final 12-week examination, mild- 
to-moderate irritation/burning/stinging, foreign body sensa-
tion, tearing, itching, and dry eye sensation were reported by 
only 16.8%, 13.9%, 15.2%, 14.9%, and 23.1% of the patients 
(Figure 1). Thus, the 12-week percentages with preservative-
free tafluprost were only around one-third of those reported 
for latanoprost at baseline.
Ocular signs
The visit-wise frequency distributions of three ocular 
signs are presented in Table 3 (blepharitis) and Table 4 
(corneal and conjunctival fluorescein staining). Blepharitis 
(mild to severe), corneal fluorescein staining (grades 
I–IV), and combined conjunctival fluorescein staining 
(grades II–VIII) were reported by 60.2%, 82.9%, and 
87.9% of the patients, respectively, at baseline with pre-
served latanoprost (Figure 2). Ocular signs also improved 
significantly after the switch to preservative-free tafluprost 
(P,0.001). The utmost severity grades became sporadic 
by the 12-week examination. For example, only three 
moderate cases of blepharitis were reported at 12 weeks. 
Consequently, blepharitis (mild to severe), corneal fluo-
rescein staining (grades I–IV), and combined conjunctival 
fluorescein staining (grades II–VIII) were reported only by 
34.2%, 41.8%, and 50.9% of the patients at the 12-week 
visit with preservative-free tafluprost (Figure 2). These 
percentages were only around one-half of those reported 
for latanoprost at baseline.
The remaining three ocular signs were evaluated 
on a continuous scale (as half grades were allowed for 
conjunctival hyperemia). The degree of conjunctival 
hyperemia was decreased from 1.51±0.76 at baseline 
Figure 1 Incidence of irritation/burning/stinging and foreign body sensation (A), tearing, itching (B), and dry eye sensation (C) at baseline during preserved latanoprost 
treatment and at 6 weeks and 12 weeks after switching to preservative-free tafluprost treatment.
Notes: The number of patients suffering from the ocular symptom is shown above each bar, and the total number of patients per visit is shown in the box. 
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with preserved latanoprost to 0.86±0.59 and 0.72±0.59 
at 6 weeks and 12 weeks, respectively, after the switch 
to preservative-free tafluprost (Table 5; P,0.001 at both 
visits). The severity of conjunctival hyperemia was thus 
halved over the 12-week treatment period, and the inci-
dence of hyperemia was also clearly reduced (Figure 2). 
tBUT was increased from 5.9±4.5 seconds at baseline with 
preserved latanoprost to 7.7±4.2 seconds at 6 weeks with 
preservative-free tafluprost (P,0.001) and 8.7±4.7 seconds 
at 12 weeks with preservative-free tafluprost (P,0.001). 
Tear production (Schirmer’s test) was also increased 
significantly from 7.8±6.9 mm at baseline with preserved 
latanoprost to 10.6±8.6 mm and 11.5±8.4 mm at 6 weeks 
and 12 weeks, respectively, with preservative-free taflu-
prost (P,0.001 at both visits).
IOP reduction
The overall mean IOP (of treated eyes) was 16.6±2.6 mmHg 
at baseline with preserved latanoprost. Further reductions 
in IOP to 16.0±2.3 mmHg and 15.7±2.5 mmHg were seen 
at 6 weeks and 12 weeks, respectively, after the switch to 
preservative-free tafluprost (P,0.001 at both visits). The 
IOP-reducing effect was thus well sustained, and overall 
IOP decreases of 3.6% (at 6 weeks) and 5.4% (at 12 weeks) 
were achieved with preservative-free tafluprost relative to 
the baseline (preserved latanoprost).
Table 4 Number (%) of patients experiencing corneal or conjunctival fluorescein staining during treatment with preserved latanoprost 
and after 6 weeks and 12 weeks of treatment with preservative-free tafluprost
Fluorescein staining Severity 
grade
Baseline preserved 
latanoprost (N=339)
6 weeks* preservative-
free tafluprost (N=318)
12 weeks* preservative-
free tafluprost (N=316)
Cornea 0 58 (17.1%) 144 (45.3%) 184 (58.2%)
i 132 (38.9%) 132 (41.5%) 109 (34.5%)
ii 125 (36.9%) 41 (12.9%) 22 (7.0%)
iii 22 (6.5%) 1 (0.3%) 1 (0.3%)
IV 2 (0.6%) 0 (0.0%) 0 (0.0%)
Conjunctivaa (combined) 0 20 (5.9%) 69 (21.7%) 102 (32.3%)
i 21 (6.2%) 59 (18.6%) 53 (16.8%)
ii 115 (33.9%) 129 (40.6%) 108 (34.2%)
iii 42 (12.4%) 22 (6.9%) 22 (7.0%)
IV 100 (29.5%) 35 (11.0%) 25 (7.9%)
V 13 (3.8%) 1 (0.3%) 3 (0.9%)
VI 25 (7.4%) 3 (0.9%) 3 (0.9%)
VII 0 (0.0%) 0 (0.0%) 0 (0.0%)
VIII 3 (0.9%) 0 (0.0%) 0 (0.0%)
Notes: *The changes from baseline at 6 weeks and 12 weeks were statistically significant; P,0.001. agrades iX and X were not reported.
Figure 2 Incidence of blepharitis, corneal staining (A) and combined conjunctival staining and conjunctival hyperemia (B) at baseline during preserved latanoprost treatment 
and at 6 weeks and 12 weeks after switching to preservative-free tafluprost treatment.
Notes: The number of patients suffering from the ocular sign is shown above each bar, and the total number of patients per visit is shown in the box.
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Drop discomfort and treatment 
preference
A majority of the patients suffered from drop discomfort at 
baseline with preserved latanoprost. Specifically, 42% of the 
patients experienced mild discomfort, 31% moderate discom-
fort, and 1% severe discomfort, whereas only ~25% of the 
patients experienced no discomfort at all. Conversely, 22% 
of the patients experienced mild discomfort, 2% moderate 
discomfort, and 76% no discomfort after 12 weeks treat-
ment with preservative-free tafluprost. The improvement 
was statistically significant (P,0.001). Furthermore, most 
of the patients clearly preferred preservative-free tafluprost 
over preserved latanoprost: up to 72% of the patients were 
in favor for tafluprost and only 6% for latanoprost when 
medication preference was evaluated as part of QoL assess-
ments (Figure 3).
Adverse events and ocular safety
A small number of treatment-related ocular adverse events 
(other than the symptoms and signs summarized in the Ocular 
symptoms and Ocular signs sections) were reported during 
the 12-week period with  preservative-free tafluprost. Only 
nine patients (2.6%) discontinued the studies due to adverse 
event(s). The majority of the events were treatment related 
and ocular. In particular, one of the discontinued patients 
experienced iritis and keratitis in the study conducted in 
Russia. The most prevalent nonocular adverse event was 
headache. Only five serious adverse events were reported, 
of which all were nonocular and not related to the treatment. 
At 12 weeks, adverse events (including ocular symptoms and 
signs) had no impact on QoL in 72% of the patients treated 
with preservative-free tafluprost. The corresponding figure 
with preserved latanoprost at baseline was only 36%.
Significant changes in visual acuity or visual fields 
that could be attributed to the treatment with preserva-
tive-free tafluprost were not seen. Moreover, no patho-
logical changes were seen in either biomicroscopy or 
ophthalmoscopy.
Discussion
The rationale of this study was to investigate whether glau-
coma patients who exhibit diminished ocular tolerability to 
BAC-preserved prostaglandin treatment with latanoprost 
would benefit from switching to a preservative-free pros-
taglandin treatment with tafluprost. A meta-analysis of two 
large Phase IIIb clinical trials – adopting essentially the 
same study protocols – was carried out to investigate this 
subject.
Evidence of BAC-induced toxicity on ocular surface has 
accumulated in recent years. BAC has shown to be toxic to 
both microorganisms and mammalian cells; hence, it may 
be associated with the surface side effects of a variety of eye 
drops.4–8,10,11 The detrimental effect of BAC is further accen-
tuated when many different eye drops preserved with BAC 
are used together, a situation that is quite frequently encoun-
tered in glaucoma treatment. Therefore, the emergence of a 
new generation of BAC-free antiglaucoma medications (or 
antiglaucoma medications with negligible concentrations of 
BAC) is extremely important.24,25
It has been further stated that BAC – through its detergent 
activity – would enhance the effectiveness of some drugs by 
facilitating their penetration into the eye and delivery to the 
cornea. Undeniably, the meta-analysis results confuted this 
obsolete claim. Equal IOP-lowering efficacy was demon-
strated between the two prostaglandin analogs, preservative-
free tafluprost and BAC-preserved latanoprost. In fact, a 
slight further decrease in IOP was seen with preservative-free 
tafluprost compared with preserved latanoprost (~1 mmHg 
at week 12).
Table 5 Degree of conjunctival hyperemia during treatment 
with preserved latanoprost and after 6 weeks and 12 weeks of 
treatment with preservative-free tafluprost
Visit Treatment N Absolutea Changea,*
Baseline Preserved latanoprost 339 1.51±0.76 –
6 weeks Preservative-free tafluprost 318 0.86±0.59 -0.64±0.79
12 weeks Preservative-free tafluprost 316 0.72±0.59 -0.78±0.82
Notes: aMean ± SD for conjunctival hyperemia scale (with half grades allowed) and 
the corresponding changes from baseline. *The changes from baseline at 6 weeks 
and 12 weeks were statistically significant; P,0.001.
Abbreviation: SD, standard deviation.
Figure 3 Patient preference on treatment options at 12 weeks.
Notes: All patients were treated with preserved latanoprost up to baseline. 
At baseline, their treatment was switched to preservative-free tafluprost for 
12 weeks.
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Considerable alleviation of all ocular symptoms and 
signs was seen during the studies after the switch from 
BAC-preserved latanoprost eye drops to preservative-free 
tafluprost eye drops. Naturally, only a subset of the symptoms 
and signs was reported by a single patient at baseline while 
on latanoprost (ie, at least two symptoms or one symptom 
and one sign were the inclusion criteria for a patient). For 
example, 29%–54% of the patients summarized in Table 3 
did not experience a specific ocular symptom at baseline with 
latanoprost. By concentrating solely on the patients who had 
at least a trace of a symptom (46%–71%), remarkable rates 
of improvement (of at least one class) were achieved with 
preservative-free tafluprost at 12 weeks: 82% for irritation/
burning/stinging, 84% for foreign body sensation, 83% for 
tearing, 78% for itching, and 83% for dry eye sensation. 
Above all, ~40% of all patients were entirely symptom free 
at the end of the 12-week treatment period.
The severity of conjunctival hyperemia was halved 
during the 12-week treatment period with preservative-free 
tafluprost (Table 5). The hyperemic effect of latanoprost 
may be largely caused by the high concentration of BAC 
(0.02%) in the ophthalmic solution, since no clear differences 
between the BAC-preserved formulations of latanoprost and 
tafluprost were seen for conjunctival hyperemia in a previ-
ous large, randomized, double-masked, Phase IIIb clinical 
trial.19 In essence, the hyperemic effect may lead to reduced 
treatment compliance. It may also be a sign of conjunctival 
inflammation. Therefore, a drug that causes less or no hype-
remia is preferable.
HLA-DR-positive conjunctival epithelial cells and 
MUC5AC-expressing goblet cells were studied in impression 
cytology specimens as part of the study conducted in Finland, 
Sweden, and Germany. Significant changes toward normal-
ization were seen during the treatment with preservative-free 
tafluprost in comparison with BAC-preserved latanoprost.20 
The results suggest that preservative-free tafluprost induces 
less harmful effects on the conjunctiva, which is the 
principal target of the toxic effects of topical ophthalmic 
preparations.
Patient-related outcomes indicated the superiority of 
preservative-free tafluprost. For example, patients’ reports 
on drop discomfort reduced substantially during the 12-week 
treatment with preservative-free tafluprost. Moreover – on 
the basis of the QoL questionnaire (COMTol) – a clear 
majority of the patients (72%) preferred preservative-free 
tafluprost over BAC-preserved latanoprost. The side effects 
had also less impact on the QoL during the treatment with 
preservative-free tafluprost.
Prostaglandin analogs have progressively replaced 
beta-blockers as the first-line therapy of OH/OAG, because 
they are the most effective IOP-lowering agents, lack relevant 
systemic side effects, and require only once-daily dosing.25,26 
Preservative-free prostaglandin analogs – such as tafluprost – 
minimize the risk of ocular side effects and increase the likeli-
hood of good treatment adherence. Hence, preservative-free 
solutions should be considered when available. They could 
be particularly beneficial to patients who 1) have preexist-
ing ocular surface disease, 2) are expected to develop ocular 
surface disease (dry eye) during long-term medication, 3) are 
using multiple concomitant topical ocular treatments, and/or 
4) are about to undergo glaucoma surgery.27,28 In general, the 
current glaucoma treatment guidelines call for therapies that 
can maintain visual function, minimize side effects, increase 
adherence, and improve QoL of the patients. A correct choice 
of first-line therapy is fundamental to achieving these patient 
outcomes and reducing the economic costs in the long run. 
Preservative-free prostaglandin analogs currently provide the 
best monotherapy option for first-line treatment of OH/OAG. 
The costs of disease management could even be halved, if 
OH/OAG is prevented/delayed effectively.29
The studies included in the meta-analysis were limited 
by their open-label designs. An open-label design could not 
be avoided, since commercial BAC-preserved latanoprost 
was available only in conventional eye drop bottles and 
preservative-free tafluprost in unit dose dispensers. The 
studies were not designed to mitigate the effect of regres-
sion to the mean (RTM) either. In other words, patients 
initially identified by high values could have lower values 
on remeasurement even in the absence of an intervention. 
A randomized, controlled study would have been the obvious 
choice to control the possible bias caused by RTM. Instead 
of RTM, the further decrease in IOP with preservative-free 
tafluprost could be attributed to improved treatment compli-
ance achieved by better tolerance. Furthermore, the limited 
12-week duration of the studies did not allow for investiga-
tion of the long-term effects.
Conclusion
The present meta-analysis confirmed that preservative-
free tafluprost eye drops offered clinical benefits to OH/
OAG patients that outweighed those of the BAC-preserved 
latanoprost eye drops. The IOP-lowering efficacy was 
sustained (or even slightly improved) after replacing 
preserved latanoprost with preservative-free tafluprost. In 
addition, preservative-free tafluprost significantly decreased 
the symptoms and signs of ocular surface disease and 
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outrated preserved latanoprost in drop comfort and treat-
ment preference.
Acknowledgments
The authors would like to thank Oy 4Pharma Ltd, Finland – 
especially Jouni Vuorinen for writing assistance and Teppo 
Huttunen for performing the meta-analysis. Study performed 
in Finland, Sweden, and Germany. Investigators in Finland: 
Kai Kaarniranta, Markku Leino, Päivi Puska, Hannu Uusitalo. 
Investigators in Sweden: Enping Chen, Elina Palmgren. 
Investigators in Germany: Thomas Hamacher, Günter Hof-
man, Gernot Petzold, Tobias Riedel, Ulrich Richter, and 
Martin Winter. Study performed in Russia: Yuriy Sergeevich 
Astakhov, Ernest Vitalyevich Boiko, Alexander Victorovich 
Doga, Evgeniy Alexeevich Egorov, Olga Alexandrovna 
Kiseleva, Alla Alexeevna Ryabtseva, and Vladimir Pavlovich 
Sergeev. The authors received editorial and writing support 
in the preparation of this manuscript, funded by Santen Oy, 
Tampere, Finland. The authors were fully responsible for the 
text, data, and editorial decisions for the paper. The manu-
script has not been presented at any meetings.
Disclosure
Auli Ropo is an employee of Santen Oy. The authors were 
investigators in the respective studies in Europe and Russia 
and received funding from Santen Oy for the study. The 
authors report no other conflicts of interest in this work.
References
1. Erb C, Gast U, Schremmer D. German register for glaucoma patients 
with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch 
Clin Exp Ophthalmol. 2008;246:1593–1601.
2. Rossi GC, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye 
syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 
2009;19:572–579.
3. Fechtner RD, Godfrey GD, Budenz D, Stewart JA, Stewart WC, Jasek MC. 
Prevalence of ocular surface complaints in patients with glaucoma 
using topical intraocular pressure-lowering medications. Cornea. 2010; 
29:618–621.
4. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms 
and signs with preserved and preservative free glaucoma medication. Br 
J Ophthalmol. 2002;86:418–423.
5. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. 
Ocular symptoms and signs with preserved and preservative-free glau-
coma medications. Eur J Ophthalmol. 2007;17:341–349.
6. Steuhl KP, Knorr M, Frohn A, Thiehl HJ. The influence of topically 
applied anti-glaucomatous eye drops on conjunctival cell differentiation. 
Fortschr Ophthalmol. 1991;88:865–869.
7. Schwab IR, Lindberg JV, Gioia VM, Benson WH, Chao GM. Foreshort-
ening of the inferior fornix associated with chronic glaucoma medica-
tions. Opthalmolology. 1992;99:197–202.
8. Broadway DC, Grierson I, Hitchings RA. Adverse effects of topical anti-
glaucomatous medications on the conjunctiva. Br J Ophthalmol. 1993; 
77:590–596.
 9. Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects 
of topical antiglaucomatous medications II: the outcome of filtration 
surgery. Arch Ophthalmol. 1994;112:1446–1454.
 10. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory 
changes induced by topical antiglaucomatous drugs: human and animal 
studies. Ophthalmology. 1999;106:556–563.
 11. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory 
and proapoptotic effects of latanoprost and preserved and unpreserved 
timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004;45: 
1360–1368.
 12. Boimer R, Birt CM. Preservative exposure and surgical outcomes in 
glaucoma patients: the PESO study. J Glaucoma. 2013;22:730–735.
 13. Nakajima T, Matsugi T, Goto W, et al. New fluoroprostaglandin F
2α 
derivatives with prostanoid FP-receptor agonistic activity as potent 
ocular-hypotensive agents. Biol Pharm Bull. 2003;26:1691–1695.
 14. Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacologic character-
istics of AFP-168 (tafluprost), a new prostanoid receptor FP agonist, 
as an ocular hypotensive drug. Exp Eye Res. 2004;78:767–776.
 15. Hamacher T, Airaksinen J, Saarela V, Liinamaa MJ, Richter V, Ropo A. 
Efficacy and safety levels of preserved and preservative-free tafluprost 
are equivalent in patients with glaucoma or ocular hypertension; results 
from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf). 2008; 
242:14–19.
 16. Sutton A, Gilvarry A, Ropo A. A comparative placebo-controlled study 
of prostanoid fluoroprostaglandin receptor agonist tafluprost and latano-
prost in healthy males. J Ocul Pharmacol Ther. 2007;23:359–365.
 17. Sutton A, Gouws P, Ropo A. Tafluprost a new potent prostanoid receptor 
agonist: a dose-response study on pharmacodynamics and tolerability 
in healthy volunteers. Int J Clin Pharmacol Ther. 2008;46:400–406.
 18. Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, efficacy and 
safety of preserved and preservative-free tafluprost in healthy volun-
teers. Acta Ophthalmol Suppl (Oxf). 2008;242:7–13.
 19. Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafluprost 
(0.0015%) versus latanoprost (0.005%) eye drops in open-angle 
glaucoma and ocular hypertension: 24-month results of a randomized, 
double-masked phase III study. Acta Ophthalmol. 2010;88:12–19.
 20. Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a 
preservative-free prostaglandin preparation in topical glaucoma medica-
tion. Acta Ophthalmol. 2010;88:329–336.
 21. Egorov EA, Astakhov YuS, Erichev VP, et al. [Evaluation of efficacy and 
safety of preservative-free tafluprost 0.0015% eye drops in patients with 
open-angle glaucoma and ocular hypertension]. RMJ Clin Ophthalmol. 
2015;16:1–6. Russian.
 22. Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA. Vali-
dation of questionnaire for comparing the tolerability of ophthalmic 
medications. Ophthalmology. 1997;104:334–342.
 23. Pocock SJ. Clinical Trials – A Practical Approach. Chichester: John 
Wiley & Sons; 1983:110–122.
 24. Niwano Y, Iwasawa A, Ayaki M. Ocular surface cytotoxicity and 
safety evaluation of tafluprost, a recently developed anti-glaucoma 
prostaglandin analog. Ophthalmol Eye Dis. 2014;6:5–12.
 25. European Glaucoma Society. Terminology and Guidelines for Glau-
coma. 4th ed. Savona: PubliComm; 2014:141–142.
 26. Boland MV, Ervin AM, Friedman DS, et al. Comparative effectiveness 
of treatments for open-angle glaucoma: a systematic review for the U.S. 
Preventive Services Task Force. Ann Intern Med. 2013;158:271–279.
 27. Baudouin C. Detrimental effect of preservatives in eyedrops: impli-
cations for the treatment of glaucoma. Acta Ophthalmol. 2008;86: 
716–726.
 28. Bagnis A, Papadia M, Scotto R, Traverso CE. Current and emerging 
medical therapies in the treatment of glaucoma. Expert Opin Emerg 
Drugs. 2011;16:293–307.
 29. Denis P. Adverse effects, adherence and cost-benefits in glaucoma 
treatment. Eur Ophthal Rev. 2011;5:116–122.
Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2016:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
454
Uusitalo et al
